COVINGTON, Ky. (Jan. 29, 2018) — CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization, announced that it has opened offices in Singapore.
The offices are opened through the wholly-owned subsidiary, CTI Clinical Trial and Consulting Services Singapore Pte. Ltd. The company has opened more than a dozen offices over the past few years, with additional international expansion planned in Asia over the next 12-18 months. The company established their Pacific-Asia headquarters in Sydney, Australia several years ago.
“The expansions in Singapore is part of continued efforts to increase our clinical research offerings across Asia,” said Patrick Earley, vice president, international. “We have been working across Asia for a number of years, and have decided that establishing a more permanent presence in Singapore and other countries in Asia would allow us to further enhance relationships with local medical centers and biotechnology companies.”
The company announced the opening of offices in Taipei, Taiwan and Tokyo, Japan in June of 2017.
CTI has been working for nearly two decades in the drug development industry across North America, Europe, South America, Pac-Asia, and Africa, specializing in clinical research programs involving critically ill patient populations, and has more than 25 offices worldwide to serve more than 120 pharmaceutical, biotechnology, and medical device clients.